This podcast was initiated and funded by Bayer Australia Ltd.
Treatment options for men with non-metastatic castrate-resistant prostate cancer (nmCRPC) now extend beyond continued androgen deprivation therapy to include the second-generation androgen-receptor inhibitors. In this podcast the limbic speaks to Doctor Neal Shore from the Carolina Urologic Research Centre in the United States and local oncologist Doctor Laurence Krieger from the Northern Cancer Institute in Sydney about the clinical benefits of these newly available treatments and the impact they’re having on the treatment paradigm for nmCRPC.
